The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues.
about
Chromogranin A is an autoantigen in type 1 diabetesDetermining the breadth of the respiratory syncytial virus-specific T cell responsePredicting Class II MHC-Peptide binding: a kernel based approach using similarity scores.Prss16 is not required for T-cell development.Identification of an I-Ed-restricted T-cell epitope of Escherichia coli outer membrane protein F.DRB1*0401-restricted human T cell clone specific for the major proinsulin73-90 epitope expresses a down-regulatory T helper 2 phenotype.Development of 2A peptide-based strategies in the design of multicistronic vectors.Accurate pan-specific prediction of peptide-MHC class II binding affinity with improved binding core identification.The relationship between immunodominance, DM editing, and the kinetic stability of MHC class II:peptide complexes.Conformational isomers of a peptide-class II major histocompatibility complex.HLA-DM constrains epitope selection in the human CD4 T cell response to vaccinia virus by favoring the presentation of peptides with longer HLA-DM-mediated half-livesMutant MHC class II epitopes drive therapeutic immune responses to cancer.Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells.Altered peptide ligands can modify the Th2 T cell response to the immunodominant 161-175 peptide of LACK (Leishmania homolog for the receptor of activated C kinase).A deimmunised form of the ribotoxin, α-sarcin, lacking CD4+ T cell epitopes and its use as an immunotoxin warhead.Understanding the focused CD4 T cell response to antigen and pathogenic organisms.T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous eventA hairpin turn in a class II MHC-bound peptide orients residues outside the binding groove for T cell recognition.Respiratory syncytial virus: current progress in vaccine development.Identification of amino acid residues in PEPHC1 important for binding to the tumor-specific receptor EGFRvIII.Single-molecule motions of MHC class II rely on bound peptides.Peptide length significantly influences in vitro affinity for MHC class II molecules.Computational Identification and Characterization of a Promiscuous T-Cell Epitope on the Extracellular Protein 85B of Mycobacterium spp. for Peptide-Based Subunit Vaccine DesignModification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4⁺ T-cell repertoire selectionImmunodominance of CD4 T cells to foreign antigens is peptide intrinsic and independent of molecular context: implications for vaccine design.Functional recombinant MHC class II molecules and high-throughput peptide-binding assays.Improved methods for predicting peptide binding affinity to MHC class II molecules.CD4 and CD8 T lymphocyte interplay in controlling tumor growth.HLA-DRB1*07:01 allele is primarily associated with the Diego a alloimmunization in a Brazilian population.Relative immunogenicity of Fya and K antigens in a Caucasian population, based on HLA class II restriction analysis.Quantification of HLA-DM-Dependent Major Histocompatibility Complex of Class II Immunopeptidomes by the Peptide Landscape Antigenic Epitope Alignment Utility.Respiratory syncytial virus vaccine development
P2860
Q24605199-DCBC3DB7-15C1-4B33-9033-98A5784059C7Q30411070-5717C2EA-C2EE-4036-B08C-334715D62ADBQ33263601-3FA97D19-3D3F-48F5-A5ED-916FA153632EQ33695404-33405B7B-FEDC-446F-BEA2-80DA47555A0BQ34756687-4F9E893B-C9F2-4DF4-BF06-7D0E8FCD9FDEQ34984492-74765487-54D1-4FA4-B59C-F5E00B46160BQ36150485-F7E16ACB-8627-4DFA-8D92-BE878B39D5ADQ36260214-CEC4B9AF-46C9-41C5-AD9D-A8DE88B2EFACQ36266503-77E2E3E4-E703-4EC8-B4F3-F1E29F1A9D28Q36266513-9183A194-A422-4396-AD99-45309B1E882EQ36303660-FC0A2DB7-E5B0-46E9-BF6F-DAE472B640D3Q36817092-5D67524D-DA6A-4EC8-8A57-C06C737E3D8DQ36909497-3480C2B5-9080-430D-A34E-FAC10BBD1708Q37137856-36DFAD65-2644-4127-8181-03E1ADD01025Q37367958-5365300A-597E-45B2-BC03-3F565B7702FAQ37386987-62514709-B24E-427E-95B2-1210593DE91EQ37389695-F75AE0B2-72A3-42CC-9D14-CB98A809818CQ37513302-8C985F80-0721-415D-BCC4-D16077A5EC8EQ38079432-1A4F16E8-FEEF-442B-977C-F6BE5247AE3BQ39930911-6E7410BA-E697-4625-A116-A6CA8D15AF9CQ41550764-E0257105-0A78-4102-8420-D3E9B037999DQ42004430-2B9A1909-C975-45D5-B186-F2DD3691E2C6Q42177811-40F64B77-C171-4426-A4E2-C903067E7DD9Q42604985-A0A110DA-B720-4BA2-BFFD-281E11679823Q42925957-550215E9-BAB9-4262-893E-044F9E824098Q43118417-02975978-F359-4E26-A56D-F12CFA3410D8Q47189829-E729D520-2256-4A41-AF74-C6FB9D60F96BQ48185876-C2C4F74C-EFAE-4A7E-993E-63417F4CEC7FQ50474053-808D5329-4758-4FD5-854A-E1C75211F07BQ50723623-A9ACAB60-D691-4C6C-B7D3-9103AFA14652Q55067919-453E9F9D-42D6-46E0-9E04-0D83CFC0474CQ56893551-34EF7841-83E9-4493-A9DD-F92602632AA1
P2860
The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
The majority of immunogenic ep ...... und peptide-flanking residues.
@en
The majority of immunogenic ep ...... und peptide-flanking residues.
@nl
type
label
The majority of immunogenic ep ...... und peptide-flanking residues.
@en
The majority of immunogenic ep ...... und peptide-flanking residues.
@nl
prefLabel
The majority of immunogenic ep ...... und peptide-flanking residues.
@en
The majority of immunogenic ep ...... und peptide-flanking residues.
@nl
P2093
P1476
The majority of immunogenic ep ...... und peptide-flanking residues.
@en
P2093
Dario A A Vignali
David L Woodland
Kate M Vignali
Nicole L La Gruta
P Scott Adams
Paula Y Arnold
Tim Miller
P304
P356
10.4049/JIMMUNOL.169.2.739
P407
P577
2002-07-01T00:00:00Z